![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00488449 |
The purpose of this study is to compare the effects of single and repeat doses of GSK256073 with placebo in HVT subjects.
Condition | Intervention | Phase |
---|---|---|
Healthy Subjects |
Drug: GSK256073A tablets |
Phase I |
Study Type: | Interventional |
Study Design: | Diagnostic, Randomized, Single Blind, Parallel Assignment, Pharmacokinetics/Dynamics Study |
Official Title: | A Two-Part Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Oral Doses of GSK256073A, in a Randomized, Single-Blind, Dose Escalation Study in Healthy Adult Subjects |
Enrollment: | 56 |
Study Start Date: | June 2007 |
Study Completion Date: | November 2007 |
Primary Completion Date: | November 2007 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years to 55 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion criteria:
Exclusion criteria:
Responsible Party: | GSK ( Study Director ) |
Study ID Numbers: | HMA110015 |
Study First Received: | June 18, 2007 |
Last Updated: | October 9, 2008 |
ClinicalTrials.gov Identifier: | NCT00488449 |
Health Authority: | United States: Food and Drug Administration |
GSK256073A, Dose Escalation |
Healthy |